Iterum Therapeutics plc (ITRM)
After hours:
| Previous Close | 0.9960 |
| Open | 1.0000 |
| Bid | 0.9899 x 100 |
| Ask | 1.0200 x 200 |
| Day's Range | 0.9800 - 1.0200 |
| 52 Week Range | 0.6220 - 2.5000 |
| Volume | |
| Avg. Volume | 315,459 |
| Market Cap | 22.82M |
| Beta (5Y Monthly) | 2.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8300 |
| Earnings Date | Aug 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
ZacksITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
Iterum provides updates from the FDA's Antimicrobial Drugs Advisory Committee meeting on its NDA for oral sulopenem to treat adult women with uUTI.
GlobeNewswireIterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
FDA Decision Expected by PDUFA Goal Date of October 25, 2024 Potential to be First Oral Penem Approved in the U.S. DUBLIN and CHICAGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced that a meeting of the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Ad
- GlobeNewswire
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
DUBLIN, Ireland and CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced that Corey Fishman, Iterum's Chief Executive Officer, will present and host investor meetings at the 26th Annual H.C. Wainwright Global Investment Conference held September 9 to September 11,
